Neurocrine Biosciences (NBIX) stock plummeted 5.01% in intraday trading on Monday, February 10th, 2025, as investors reacted to the company's lackluster fourth-quarter earnings and conservative outlook for the year.

Despite revenue increasing by 21.8% year-over-year to $627.7 million in Q4, NBIX's net income dropped 30% to $103.1 million from $147.7 million in the same period last year. For the full year 2024, revenue grew 24.8% to $2.355 billion, while net income rose 36.68% to $341.3 million.

However, the company's guidance for 2025 fell short of expectations, projecting full-year net product sales between $2.5 billion and $2.6 billion. Investors viewed this outlook as conservative, leading to the stock's sharp decline. NBIX's CEO Kyle Gano remained optimistic, stating, "With a rapidly advancing and growing pipeline and a strong financial profile, we are well positioned to build a leading neuroscience company."